Prevention of Developmental Delay and Xylitol (PDDaX) Study
Recruiting
N/A
Interventional Study
Prematurity
Neurodevelopmental Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 4 – 8
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 1,000 (estimated)
- Sponsor
- University of Washington · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goals of this study are to: evaluate and validate the low-cost, transportable, easily-administered Malawi Developmental Assessment Tool (MDAT) for neurodevelopmental assessment of children aged 4-8 years old in Malawi, as compared to the gold-standard yet more cumbersome and costly Kaufman Assessment Battery for Children-II (KABC-II) among (1) n=500 formerly preterm children and (2) n=500 form…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Child born during the PPaX trial
* Enrollment age between 4-8 years old
* Parental or legal guardian consent obtained
* Willing to undergo 3 neurodevelopmental tests
* Willing to travel to BCMF for neurodevelopmental assessment
* Assent by the pediatric subject for participati…
Contacts